Kardigan
Coverage of Kardigan in the Nexus archive.
- Kardigan: Q2 Earnings Snapshot
Kardigan Inc. reported a loss of $116.2 million and $4.61 per share for its second quarter. The Princeton, New Jersey-based company noted that adjusted losses came to $2.88 per share.
- Heart Health Biotech Kardigan Raises $400 Million in Upsized IPO
Kardigan, a heart health biotech company, raised $400 million in an upsized IPO. The company focuses on heart health innovations and has successfully secured significant funding through its initial public offering.
- Heart drug developer Kardigan is targeting a $1.4 billion valuation in its U.S. IPO
Kardigan, a heart drug developer, is targeting a $1.4 billion valuation through its U.S. IPO. The company plans to raise up to $373.3 million by selling 23.3 million shares priced between $14 and $16 each.
- Heart Health Biotech Kardigan Seeks $373.3 Million in US IPO
Heart Health Biotech Kardigan is seeking $373.3 million through a US IPO. The company's technology, including Arineta's SpotLight Duo mobile CT scanner, is being used at Clarity Mobile Cardiac CT clinics in Riverside, CA.
- Kardigan Files for IPO to Fund Cardiovascular Disease Treatment
Kardigan has filed for an IPO to fund the development of treatments for cardiovascular disease. A young female scientist is highlighted as conducting research in a lab related to this initiative.